Volume change rate ranking (14:00) ~ Almedio, Sumiseki HD, etc. are ranked
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/17 14:33 as of] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate <7859> Almedio 9978200 223680 357.79% -0.154
Sun Bio, Plaid [Emerging Markets Rating List]
“Mizuho” <4592>Sun Bio Neutral Installation “Morgan” <4165>Plaid EQUALWEIGHT Deposition*The ratings of the above companies were confirmed by us as of 04/03.
Kameda Confectionery, DIC, etc. (additional) Rating
Target Stock Price Change Code | Stock Name | Securities Company | Conventional | After Change |------|---------------|----------|-----------|--------|<2220>|Kameda Confectionery | Nomura | 4000 yen | 4350 yen |<2809>|Kewpie |Morgan S | 2700 yen | 2800 yen |<2914>|JT |SMBC Nikko
Sun Bio [Emerging Markets Ratings List]
“City” <4592>Sun Bio downgraded 1 → 2. *The ratings for each company above were confirmed by us as of 04/02.
Mitsui Gold, Resonac HD, etc. (additional) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|--------------|--------------|--------------|<3593>|Hogimedy |Morgan S | “Under W” | “Equal W” |<8086>| Nipro | Morgan S | “Equal W” | “Equal W” | “Over W” | “Over W” | Downgraded - Bearish Cow
Emerging market outlook: The search centered on recent IPO stocks continues, but will funds go to the main market as we enter the new fiscal year
■There is no interest in the main stocks due to daily speculation centered on IPOs, and the emerging market declined this week. The gain/fall rate for the same period was almost similar to the Nikkei Average of -1.27%, while the Tokyo Stock Exchange Growth Market Index was -1.12% and the Tokyo Stock Exchange Growth Market 250 Index was -1.16%. While trading related to supply and demand associated with the end of the March fiscal year entered the center of the Tokyo Stock Exchange Prime Market, interest in main stocks became difficult due to daily searching centered on IPOs (initial public offerings) in emerging markets. Tokyo Stock Exchange
The Tokyo Stock Exchange Growth Index continued to decline for 5 days, and the daily search for recent IPO stocks continues
Tokyo Stock Exchange Growth Market Index 924.28 -5.47/ trading volume 11548 shares/ trading price 174.4 billion yen Tokyo Stock Exchange Growth Market 250 Index 734.79 -4.44/ turnover 59.19 million shares/ trading price 78.1 billion yen Today's growth market continued to decline for 5 days for both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index. The number of rising stocks is 211, the number of falling stocks is 311, and 38 unchanged. The US market rebounded on the 27th. The Dow average is higher by $477.75 (+1.22
Hakuhodo DY, Dentsu G, etc. (added) Rating
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|-------------|-------------|--------------|--------------|<4751>|Cyber | City | “3” | “2” |<5214>|NIPPON Nitro Co., Ltd. |JPM | “Neutral” | “Over W
Rating [securities companies' ratings]
Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|---------------|-----------|-----------------|<5214>|Nitten Nitro Nitro |JP Morgan | “Neutral” | “Over W” |<2922>| Natori | Tokai Tokyo | “Neutral”
The Tokyo Stock Exchange Growth Index continued to decline for 4 days, and trading prices also declined due to IPO-centered positions
TSE Growth Market Index 929.75 -5.61/volume 11391 shares/ trading price 168.3 billion yen TSE growth market 250 index 739.23 -4.80/ turnover 66.99 million shares/ trading price 89.7 billion yen Today's growth market continued to decline for 4 days with both the TSE Growth Market Index and TSE Growth Market 250 Index. The number of rising stocks is 234, the number of falling stocks is 297, and 38 unchanged. The US market continued to decline on the 26th. The Dow Average depreciated by $31.31 (-0.08%)
SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March
SanBio(TYO:4592) plans to gain marketing approval for SB623, a product for treating chronic traumatic brain injury in Japan by March, and is actively participating in the review process, according to
Jefferies Adjusts SanBio's Price Target to 270 Yen From 310 Yen, Keeps at Underperform
05:02 AM EDT, 03/19/2024 (MT Newswires) -- Jefferies Adjusts SanBio's Price Target to 270 Yen From 310 Yen, Keeps at Underperform
SanBio Books Non-operating Income, Extraordinary Gains, Deferred Income Taxes in Fiscal 2024
SanBio (TYO:4592) reported non-operating income, extraordinary gains, and deferred income taxes for the fiscal year ending on Jan. 31, according to its bourse filing on Monday. It accumulated a non-op
SanBio's FY2024 Attributable Net Loss Narrows on Lower Costs, Forex Gains
SanBio (TYO:4592) significantly narrowed its fiscal 2024 attributable net loss after recording foreign exchange gains as non-operating income and expenses decreased. The drugmaker's attributable net l
SanBio FY Loss Y2.64B Vs Loss Y5.56B
SanBio FY Loss Y2.64B Vs Loss Y5.56B
SanBio Liquidates Singapore Unit
SanBio (TYO:4592) completed the liquidation of its Singapore-based subsidiary, SanBio Asia, on Feb. 5, according to a Wednesday bourse filing. The Japanese pharmaceutical company expects the impact of
SanBio to Cancel Certain Stock Options
SanBio (TYO:4592) will proceed to acquire and subsequently cancel a total of 127,800 stock options on Jan. 25. The stock options being canceled are those that have been granted to awardees who are no
SanBio Logs Extraordinary Gain From Asset Sale of US Unit
SanBio (TYO:4592) recorded an extraordinary gain amounting to 26 million yen from the sale of non-current assets of a consolidated US subsidiary, The pharmaceutical company said the unit sold certain
Sanbio Widens Nine-Month Attributable Net Loss
Sanbio (TYO:4592) posted a wider nine-month attributable net loss after recording extraordinary losses on the retirement of non-current assets. The biotech company's attributable net loss was 1.88 bil
Sanbio Cuts Staff Amid Restructuring of Overseas Subsidiary
Sanbio (TYO:4592) reduced its headcount by 22 employees on Nov. 30 amid a restructuring process of its overseas subsidiary, according to a Thursday bourse filing. The biotech company expects the move
No Data